|
||
Independent, up-to-date news and information for the multiple myeloma community. |
|
Results of a recent British study indicate that the relative importance of factors affecting survival in multiple myeloma patients changes with patient age.
In particular, the researchers found that the older a patient is at diagnosis, the more their survival is affected by their general health and by how advanced their multiple myeloma is at diagnosis.
In contrast, the impact of high-risk chromosomal abnormalities on survival decreases with patient age.
The study findings are based on an analysis of data …
A team of Dutch researchers has published results of a small study investigating the impact of Darzalex treatment on immunoglobulin levels in multiple myeloma patients.
In their study, the researchers focus in particular on how the levels of a patient’s uninvolved immunoglobulins are affected by treatment with Darzalex.
Uninvolved immunoglobulins in myeloma patients are immunoglobulins that have a type different from any monoclonal immunoglobulin made by a patient’s myeloma cells.
Someone with IgG multiple myeloma, for example, has myeloma plasma …
Swiss researchers have published results of a small clinical trial testing whether nelfinavir, a drug originally used to treat AIDS, can overcome resistance to Revlimid in relapsed multiple myeloma patients.
The trial was motivated by previous research showing that nelfinavir can overcome resistance to Velcade, for a period of time, in many relapsed myeloma patients.
Unfortunately, the results of the more recent nelfinavir trial are not as encouraging as the previous research involving nelfinavir and Velcade. Less than a third …
A team of U.S. researchers has published the results of an investigation into eyelid-related complications in multiple myeloma patients receiving treatment with Velcade or Kyprolis. Drawing on the results of their investigation, the authors of the new study also propose guidelines for the prevention and management of such complications.
The authors report on a case series of 16 patients who developed either blepharitis or chalazia after starting treatment with Velcade (bortezomib) or Kyprolis (carfilzomib).
Blepharitis is the medical term for …
Italian researchers have found that common measures of heart and blood vessel health may predict the risk of heart-related side effects in multiple myeloma patients treated with Kyprolis (carfilzomib).
In particular, the researchers found that myeloma patients who experienced heart-related side effects while being treated with Kyprolis had significantly higher blood pressure, left ventricular mass, and pulse wave velocity before starting Kyprolis treatment than patients who did not experience heart-related side effects.
Blood pressure, left ventricular mass, and pulse wave …
Results of a recent retrospective study show that radiation therapy shortly before, or shortly after, the start of drug-based treatment in newly diagnosed multiple myeloma patients is associated with lower overall survival.
The results are based on information for 78,095 multiple myeloma patients from the United States whose data were reported to the National Cancer Data Base between 2004 and 2015.
For their retrospective analysis, the authors of the new study divided the 78,095 patients in their sample into two …
An international team of researchers recently found that people with MGUS who consumed fruit at least three times a week had a lower risk of progressing to multiple myeloma than people with MGUS who consumed fruit less frequently.
The impact of higher fruit consumption on risk of progression was sizable. The statistical models developed by the researchers indicate that eating fruit three times or more each week cut the risk of progression by at least a half.
The researchers also …
